NORLIQVA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norliqva, and what generic alternatives are available?
Norliqva is a drug marketed by Cmp Dev Llc and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in NORLIQVA is amlodipine besylate. There are fifty drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the amlodipine besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norliqva
A generic version of NORLIQVA was approved as amlodipine besylate by COREPHARMA on May 23rd, 2007.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NORLIQVA?
- What are the global sales for NORLIQVA?
- What is Average Wholesale Price for NORLIQVA?
Summary for NORLIQVA
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 125 |
| Drug Prices: | Drug price information for NORLIQVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NORLIQVA |
| What excipients (inactive ingredients) are in NORLIQVA? | NORLIQVA excipients list |
| DailyMed Link: | NORLIQVA at DailyMed |
Pharmacology for NORLIQVA
| Drug Class | Dihydropyridine Calcium Channel Blocker Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A Inhibitors |
US Patents and Regulatory Information for NORLIQVA
NORLIQVA is protected by eighteen US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
